Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells

Journal of Cellular Physiology

Volumn 227, Issue 7, 2012, Pages 2907-2916

  Liu, Qi ^a   Xi, Yutao ^a   Terry, Toya ^a   So, Shui Ping ^b   Mohite, Anita ^b   Zhang, Jia ^a   Wu, Geru ^a   Liu, Xiaobing ^a   Cheng, Jie ^a   Ruan, Ke He ^b   Willerson, James T ^a   Dixon, Richard A F ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOOXYGENASE 1; POTASSIUM CHANNEL; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; SMALL INTERFERING RNA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DENSITY; CELL ENGINEERING; CELL GROWTH; CELL HYPOXIA; CELL PROLIFERATION; CELL PROTECTION; CELL THERAPY; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; GENE SILENCING; HUMAN; HYPERPOLARIZATION; IN VITRO STUDY; NONHUMAN; PATCH CLAMP; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

4-AMINOPYRIDINE; ANIMALS; ANOXIA; APOPTOSIS; CELL ENGINEERING; CELL GROWTH PROCESSES; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 1; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HALF-LIFE; INTRAMOLECULAR OXIDOREDUCTASES; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; POTASSIUM CHANNELS; RATS; RECOMBINANT FUSION PROTEINS; STEM CELLS; TRANSFECTION;

RATTUS;

EID: 84863351098     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.23035     Document Type: Article

References (28)

1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967.
2. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. 1999. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221-228.
3. Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, Barst RJ. 2004. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43: 56S-61S.
4. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW, For the Primary Pulmonary Hypertension Study Group. 1996. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296-302.
5. Bellien J, Thuillez C, Joannides R. 2008. Contribution of endothelium-derived hyperpolarizing factors to the regulation of vascular tone in humans. Fundam Clin Pharmacol 22: 363-377.
6. Duffy SJ, Castle SF, Harper RW, Meredith IT. 1999. Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation 100: 1951-1957.
7. Feletou M, Vanhoutte PM. 2006. Endothelium-derived hyperpolarizing factor: Where are we now? Arterioscler Thromb Vasc Biol 26: 1215-1225.
8. He T, Lu T, d'Uscio LV, Lam CF, Lee HC, Katusic ZS. 2008. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res 103: 80-88.
9. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. 2003. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600.
10. Hirschi KK, Ingram DA, Yoder MC. 2008. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 28: 1584-1595.
11. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, Pollok K, Ferkowicz MJ, Gilley D, Yoder MC. 2004. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 104: 2752-2760.
12. Kawabe J, Yuhki K, Okada M, Kanno T, Yamauchi A, Tashiro N, Sasaki T, Okumura S, Nakagawa N, Aburakawa Y, Takehara N, Fujino T, Hasebe N, Narumiya S, Ushikubi F. 2010. Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling. Arterioscler Thromb Vasc Biol 30: 464-470.
13. Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, Kuwabara K. 2007. 2-[4-[(5, 6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetam ide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 322: 1181-1188.
14. Liu Q, Chen ZQ, Bobustuc GC, McNatt JM, Segall H, Pan S, Willerson JT, Zoldhelyi P. 2005. Local gene transduction of cyclooxygenase-1 increases blood flow in injured atherosclerotic rabbit arteries. Circulation 111: 1833-1840.
15. McLaughlin VV, Shillington A, Rich S. 2002. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 106: 1477-1482.
16. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Moliterno DJ, Mukherjee D, Pohost GM, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ, ACCF/AHA. 2009. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119: 2250-2294.
17. Mitchell JA, Warner TD. 2006. COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 5: 75-86.
18. Moncada S, Gryglewski R, Bunting S, Vane JR. 1976. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665.
19. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S. 1997. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388: 678-682.
20. Numaguchi Y, Naruse K, Harada M, Osanai H, Mokuno S, Murase K, Matsui H, Toki Y, Ito T, Okumura K, Hayakawa T. 1999. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 19: 727-733.
21. Parkington HC, Coleman HA, Tare M. 2004. Prostacyclin and endothelium-dependent hyperpolarization. Pharmacol Res 49: 509-514.
22. Ruan KH, So SP, Cervantes V, Wu H, Wijaya C, Jentzen RR. 2008. An active triple-catalytic hybrid enzyme engineered by linking cyclo-oxygenase isoform-1 to prostacyclin synthase that can constantly biosynthesize prostacyclin, the vascular protector. FEBS J 275: 5820-5829.
23. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM. 2005. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation 111: 2981-2987.
24. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP. 1998. Evidence for circulating bone marrow-derived endothelial cells. Blood 92: 362-367.
25. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. 1999. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5: 434-438.
26. Vanhoutte PM. 2009. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J 73: 595-601.
27. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. 2001. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: E1-E7.
28. Waldron GJ, Cole WC. 1999. Activation of vascular smooth muscle K+ channels by endothelium-derived relaxing factors. Clin Exp Pharmacol Physiol 26: 180-184.